Entering text into the input field will update the search result below

Palisade Bio rises on positive mid-stage data for post-surgery medication

Jul. 29, 2021 8:41 AM ETPalisade Bio, Inc. (PALI) StockPALIBy: Dulan Lokuwithana, SA News Editor

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.
JuSun/iStock via Getty Images

  • Palisade Bio (NASDAQ:PALI) has added ~12.3% in the pre-market after announcing positive topline data from a Phase 2 trial for LB1148 in patients undergoing bowel resection surgery.
  • The multicenter, double-blind trial conducted by Palisade Bio in partnership with Newsoara

Recommended For You

More Trending News

About PALI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PALI--
Palisade Bio, Inc.